TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB announced its participation in the Aktiespararnas Stora Aktiedagar, where CEO Jens Lindberg will discuss the company’s upcoming Right’s Issue intended to fund a study comparing their drug candidate fostrox in combination with lenvatinib against lenvatinib alone for second-line liver cancer treatment. This presentation highlights Medivir’s strategic efforts to advance its drug development pipeline and strengthen its position in the oncology sector, potentially impacting stakeholders by showcasing the company’s commitment to addressing unmet medical needs in cancer treatment.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company that specializes in developing innovative cancer treatments, particularly in areas with high unmet medical needs. The company focuses on creating drug candidates for indications where existing therapies are limited or unavailable, aiming to provide significant improvements for patients. Medivir’s primary focus is on fostroxacitabine bralpamide (fostrox), a drug candidate targeting liver cancer cells while minimizing side effects. The company operates through collaborations and partnerships and is listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 732,518
Technical Sentiment Signal: Sell
Current Market Cap: SEK50.47M
Learn more about MVIR stock on TipRanks’ Stock Analysis page.